Synthekine

Executive Summary

Synthekine is a private biotechnology company pioneering the development of selective cytokine therapeutics for cancer and inflammatory diseases. Founded in 2019 and headquartered in Menlo Park, California, the company leverages its proprietary protein engineering platform to create cytokine agonists that target specific immune cell subsets, aiming to enhance efficacy while minimizing toxicity. Lead programs include STK-012, a PD-1-targeted IL-2 partial agonist in Phase 1/2 for solid tumors, and STK-009, a CD19-targeted IL-18 fusion protein in Phase 1 for B-cell malignancies. These candidates represent a novel approach to cytokine therapy designed to overcome the historical limitations of systemic cytokine administration. With a focus on selectivity and controlled immune activation, Synthekine's pipeline has the potential to improve outcomes across multiple oncology indications and expand into autoimmune indications. The company is well-positioned with a strong scientific foundation and experienced leadership, though it remains in early clinical stages with no approved products.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data readout for STK-012 in solid tumors70% success
• Q3 2026Phase 1 safety and preliminary efficacy data for STK-009 in B-cell malignancies60% success
• TBDPotential partnership or financing announcement to support pipeline advancement50% success